[1] Kim SH, Song MK, Joung JY, et al. Significant clinicopathologic prognostic factors for bladder recurrence, progression, and cancer-specific survival after surgery among patients with upper urinary tract urothelial carcinoma[J]. Investig Clin Urol, 2019, 60: 432-442. [2] Lu CS, Shieh GS, Wang CT, et al. Chemotherapeutics-induced Oct4 expression contributes to drug resistance and tumor recurrence in bladder cancer[J]. Oncotarget, 2017, 8: 30844-30858. [3] Wang LH, Shang L, Shan DY, et al. Long-term floating control-released intravesical preparation of 5-fluorouracil for the local treatment of bladder cancer[J]. Drug Dev Ind Pharm, 2017, 43: 1343-1350. [4] Rupaimoole R, Slack FJ. microRNA therapeutics: towards a new era for the management of cancer and other diseases[J]. Nat Rev Drug Discov, 2017, 16: 203-222. [5] Sun R, Liu Z, Tong D, et al. miR-491-5p, mediated by Foxi1, functions as a tumor suppressor by targeting Wnt3a/β-catenin signaling in the development of gastric cancer[J]. Cell Death Dis, 2017, 8: e2714. doi:10.1038/cddis.2017.134. [6] Zhang J, Raju GS, Chang DW, et al. Global and targeted circulating microRNA profiling of colorectaladenoma and colorectal cancer[J]. Cancer, 2018, 124: 785-796. [7] Zhang Y, Xu W, Ni P, et al. miR-99a and miR-491 regulate cisplatin resistance in human gastric cancer cells by targeting CAPNS1[J]. Int J Biol Sci, 2016, 12: 1437-1447. [8] Wang SN, Luo S, Liu C, et al. miR-491 inhibits osteosarcoma lung metastasis and chemoresistance by targeting αB-crystallin[J]. Mol Ther, 2017, 25: 2140-2149. [9] 刘进生,黄良祥,李建党,等. miR-140-5p调控Nrf2影响结肠癌细胞5-FU耐药性[J]. 中国癌症防治杂志, 2018, 10: 193-198. [10] Chen Y, Lian G, Ou G, et al. Inverse association between Bmi-1 and RKIP affecting clinical outcome of gastric cancer and revealing the potential molecular mechanisms underlying tumor metastasis and chemotherapy resistance[J]. Gastric Cancer, 2016, 19: 392-402. [11] Galletti G, Leach BI, Lam L, et al. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer[J]. Cancer Treat Rev, 2017, 57: 16-27. [12] Wang H, Luo Y, Qiao T, et al. Luteolin sensitizes the antitumor effect of cisplatin in drug-resistant ovarian cancer via induction of apoptosis and inhibition of cell migration and invasion[J]. J Ovarian Res, 2018, 11: 93. doi: 10.1186/s13048-018-0468-y. [13] Zhou H, Huang HY, Shapiro E, et al. Urothelial tumor initiation requires deregulation of multiple signaling pathways: implications in target-based therapies[J]. Carcinogenesis, 2012, 33: 770-780. [14] Anand V, Khandelwal M, Appunni S, et al. CD44 splice variant (CD44v3) promotes progression of urothelial carcinoma of bladderthrough Akt/ERK/STAT3 pathways: novel therapeutic approach[J]. J Cancer Res Clin Oncol, 2019, 145: 2649-2661. |